Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial

被引：1
|
作者：
de Souza, M. S. [1 ]
Trichavaroj, R. [1 ]
Schuetz, A. [1 ]
Chuenarom, W. [1 ]
Phuang-ngem, Y. [1 ]
Jongrakthaitae, S. [1 ]
Ratto-Kim, S. [2 ]
Nitayaphan, S. [1 ]
Dally, L. [3 ]
Rerks-Ngam, S. [4 ]
Tartaglia, J. [5 ]
Francis, D. [6 ]
Michael, N. L. [2 ]
Paris, R. M. [1 ]
Kim, J. H. [2 ]
机构：
[1] US Mil HIV Res Program AFRIMS, Bangkok, Thailand
[2] US Mil HIV Res Program, Rockville, MD USA
[3] EMMES Corp, Rockville, MD USA
[4] Minist Publ Hlth, Nonthaburi, Thailand
[5] Sanofi Pasteur, Toronto, ON, Canada
[6] Global Solutat Infect Dis, San Francisco, CA USA
来源：
RETROVIROLOGY | 2009年 / 6卷
关键词：
Humoral Immune Response; Vaccine Candidate; Vaccine Trial; Recombinant Form; Vaccine Antigen;
D O I：
10.1186/1742-4690-6-S3-O52
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immune Correlates of Infection Risk in the Thai Phase III ALVAC-HIV/AIDSVA-B/E Prime Boost Study
    Michael, Nelson L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 : 46 - 46
  • [22] OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
    JH Kim
    C Kamasuta
    R Trichavaroj
    J Kaewkungwal
    S Chantakulkij
    S Ratto-Kim
    C Eamsila
    S Sukwit
    S Nitayaphan
    P Pitsuttihum
    NL Michael
    J Chiu
    S Rerks-Ngarm
    MS de Souza
    RM Paris
    Retrovirology, 6
  • [23] Delayed Boost of ALVAC®HIV and AIDSVAX® B/E gp120 Following the RV144 Regimen, Significantly Increases HIV-1 Neutralizing Antibody Responses
    Wieczorek, Lindsay
    Pitisutthithum, Punnee
    Nitayaphan, Sorachai
    Chariyalertsak, Suwat
    Kaewkungwal, Jaranit
    Molnar, Sebastian
    Blaskowski, Stephen
    Schoen, Jesse
    Gao, Hongmei
    Greene, Kelli
    Phogat, Sanjay
    Sinagil, Faruk
    Michael, Nelson
    Excler, Jean-Louis
    Montefiori, David
    Robb, Merlin
    Kim, Jerome
    Vasan, Sandhya
    Connell, Robert O.
    Polonis, Victoria
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 100 - 100
  • [24] Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses
    Huang, Ying
    Alam, Shomoita
    Andersen-Nissen, Erica
    Carpp, Lindsay N.
    Dintwe, One B.
    Flach, Britta S.
    Grunenberg, Nicole
    Laher, Fatima
    De Rosa, Stephen C.
    Ferrari, Guido
    Innes, Craig
    Bekker, Linda-Gail
    Kublin, James G.
    McElrath, M. Juliana
    Tomaras, Georgia D.
    Gray, Glenda E.
    Gilbert, Peter B.
    VIRUSES-BASEL, 2024, 16 (09):
  • [25] Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants
    Frey, Sharon E.
    Peiperl, Laurence
    McElrath, M. Juliana
    Kalams, Spyros
    Goepfert, Paul A.
    Keefer, Michael C.
    Baden, Lindsey R.
    Lally, Michelle A.
    Mayer, Kenneth
    Blattner, William A.
    Harro, Clayton D.
    Hammer, Scott M.
    Gorse, Geoffrey J.
    Hural, John
    Tomaras, Georgia D.
    Levy, Yves
    Gilbert, Peter
    deCamp, Allan
    Russell, Nina D.
    Elizaga, Marnie
    Allen, Mary
    Corey, Lawrence
    CLINICAL AND VACCINE IMMUNOLOGY, 2014, 21 (11) : 1589 - 1599
  • [26] Characterization of HIV-1 Envelope Antibody Responses Following ALVAC-HIV and AIDSVAX B/E Prime-boost Vaccinations with Varying Late Boosts (RV306)
    Akapirat, Siriwat
    Madnote, Sirinan
    Pitisuttithum, Punnee
    Nitayaphan, Sorachai
    Chariyalertsak, Suwat
    Puangkaew, Jiraporn
    Rittiroongrad, Surawach
    Chantakulkij, Somsak
    Phogat, Sanjay
    Sinangil, Faruk
    Excler, Jean-Louis
    Robb, Merlin L.
    Michael, Nelson L.
    Kim, Jerome H.
    Vasan, Sandhya
    Connell, Robert J. O.
    Karasavvas, Nicos
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 100 - 100
  • [27] RV306, an Evaluation of a 48 Week ALVAC-HIV AIDSVAX B/E Vaccination Regimen in Thailand: Participation Rates for Optional Specimen Collections
    Pitisuttithum, Punnee
    Nitayaphan, Sorachai
    Chariyalertsak, Suwat
    Karasavvas, Nicos
    Kaewkungwal, Jaranit
    Ngauy, Viseth
    Vasan, Sandhya
    Robb, Merlin L.
    Michael, Nelson L.
    Brown, J. Kendall
    Andrews, Charla
    Phonrat, Benjaluck
    Dhitavat, Jittima
    Excler, Jean Louis
    Kim, Jerome H.
    O'Connell, Robert J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A264 - A264
  • [28] Late Boost Strategies of ALVAC-HIV/AIDSVAX B/E® Prime-boost Regimen (RV306) Increased Functional B Cell Responses and Frequency of Plasmablasts
    Chuenarom, Weerawan
    Pitisutthithum, Punnee
    Phuangngern, Yuwadee
    Nitayaphan, Sorachai
    Chariyalertsak, Suwat
    Kaewkungwal, Jaranit
    Kaewboon, Boot
    Phogat, Sanjay
    Karasavvas, Nicos
    Sinangil, Faruk
    Excler, Jean-Louis
    Robb, Merlin
    Michael, Nelson
    Kim, Jerome
    Desouza, Mark
    Connell, Robert O.
    Vasan, Sandhya
    Schuetz, Alexandra
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 393 - 393
  • [29] Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand
    Karnasuta, C
    Paris, RM
    Cox, JH
    Nitayaphan, S
    Pitisuttithum, P
    Thongcharoen, P
    Brown, AE
    Gurunathan, S
    Tartaglia, J
    Heyward, WL
    McNeil, JG
    Birx, DL
    de Souza, MS
    VACCINE, 2005, 23 (19) : 2522 - 2529
  • [30] Vaccination with ALVAC-HIV/AIDSVAX® B/E of Non-human Primates (NHPs) Elicits Distinct Mucosal and Systemic Responses
    Herrera, Carolina
    Veazey, Ronald
    Lemke, Melissa
    Olejniczak, Natalia
    Arnold, Kelly
    Kim, Jerome H.
    Shattock, Robin J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 306 - 306
12345